

EFS

Applicant: David S. Lawrence

Appl'n. No.: 10/589,029

Filed: June 21, 2007

Reply filed August 20, 2010


Page 12 of 21

Amendments to the Claims:


Please amend Claims 1, 8 and 99-102 as set forth below:

1. (Currently amended) An inhibitor of a protein kinase $C\alpha$ ($PKC\alpha$), the inhibitor comprising


A-Ala-Arg-Arg-X-B-Hyd-C-D- (SEQ ID NO:1), where A =AcHN-,



X=any amino acid or amino acid-mimetic; B=Ala or a diaminopropionic acid (Dap) derivative having the formula



Hyd=Phe, Leu or Ile; C=Arg or Lys; and D=Ala or a Dap derivative having the formula



wherein any of the amino acids can alternatively be an analogous amino acid-mimetic.

2-6. (Canceled)

7. (Original) The inhibitor of claim 1, wherein the $PKC\alpha$ is a human $PKC\alpha$.

8. (Currently amended) An inhibitor of a protein kinase $C\alpha$ ($PKC\alpha$), the inhibitor

EFS

Applicant: David S. Lawrence


Appl'n. No.: 10/589,029

Filed: June 21, 2007


Reply filed August 20, 2010

Page 13 of 21


The inhibitor of claim 1, comprising




(SEQ ID NO:2),




(SEQ ID NO:2),



(SEQ ID NO:2),



(SEQ ID NO:2),



(SEQ ID NO:2), or

EFS


Applicant: David S. Lawrence

Appl'n. No.: 10/589,029

Filed: June 21, 2007

Reply filed August 20, 2010

Page 14 of 21



9-93. (Canceled)

94. (Previously presented) The inhibitor of claim 1, having an $IC_{50} < 50 \mu M$ for the $PKC\alpha$.

95. (Previously presented) The inhibitor of claim 1, having an $IC_{50} < 10 \mu M$ for the $PKC\alpha$.

96. (Previously presented) The inhibitor of claim 1, having an $IC_{50} < 1 \mu M$ for the $PKC\alpha$.

97. (Previously presented) The inhibitor of claim 1, wherein the inhibitor has an IC_{50} for the $PKC\alpha < 0.1$ that of any other PKC isoform.

98. (Previously presented) The inhibitor of claim 1, wherein the inhibitor has an IC_{50} for the $PKC\alpha < 0.01$ that of any other PKC isoform.

99. (Currently amended) The inhibitor of claim 8[[1]], comprising

EFS


Applicant: David S. Lawrence

Appl'n. No.: 10/589,029


Filed: June 21, 2007

Reply filed August 20, 2010


Page 15 of 21




100. (Currently amended) The inhibitor of claim 8[[1]], consisting of




101. (Currently amended) The inhibitor of claim 8[[1]], comprising




102. (Currently amended) The inhibitor of claim 8[[1]], consisting of




103. (Previously presented) The inhibitor of claim 1, comprising




104 (Previously presented) The inhibitor of claim 1, consisting of



105. (Previously presented) The inhibitor of claim 1, comprising



106. (Previously presented) The inhibitor of claim 1, consisting of



107. (Previously presented) The inhibitor of claim 1, comprising

EFS


Applicant: David S. Lawrence

Appl'n. No.: 10/589,029

Filed: June 21, 2007


Reply filed August 20, 2010

Page 17 of 21




(SEQ ID NO:2).

108. (Previously presented) The inhibitor of claim 1, consisting of



(SEQ ID NO:2).

109. (Previously presented) The inhibitor of claim 1, comprising



(SEQ ID NO:2).

110. (Previously presented) The inhibitor of claim 1, consisting of

EFS

Applicant: David S. Lawrence

Appl'n. No.: 10/589,029

Filed: June 21, 2007

Reply filed August 20, 2010

Page 18 of 21

